Cargando…
High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease
Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfuncti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030281/ https://www.ncbi.nlm.nih.gov/pubmed/27708582 http://dx.doi.org/10.3389/fphar.2016.00323 |
_version_ | 1782454648945246208 |
---|---|
author | Gordon, Elizabeth M. Figueroa, Debbie M. Barochia, Amisha V. Yao, Xianglan Levine, Stewart J. |
author_facet | Gordon, Elizabeth M. Figueroa, Debbie M. Barochia, Amisha V. Yao, Xianglan Levine, Stewart J. |
author_sort | Gordon, Elizabeth M. |
collection | PubMed |
description | Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol efflux and anti-inflammatory properties in the setting of disease or the acute phase response. These paradigms are increasingly being recognized to be active in the pulmonary system, where apoA-I and HDL have protective effects in normal lung health, as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however, HDL may become dysfunctional and contribute to disease pathogenesis in respiratory disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have protective effects in animal models of ALI, asthma, pulmonary hypertension, and influenza pneumonia. These findings provide evidence to support the concept that apoA-I mimetic peptides might be developed into a new treatment that can either prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the lung is positioned to take a page from the cardiovascular disease playbook and utilize the protective properties of HDL and apoA-I as a novel therapeutic approach. |
format | Online Article Text |
id | pubmed-5030281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50302812016-10-05 High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease Gordon, Elizabeth M. Figueroa, Debbie M. Barochia, Amisha V. Yao, Xianglan Levine, Stewart J. Front Pharmacol Pharmacology Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol efflux and anti-inflammatory properties in the setting of disease or the acute phase response. These paradigms are increasingly being recognized to be active in the pulmonary system, where apoA-I and HDL have protective effects in normal lung health, as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however, HDL may become dysfunctional and contribute to disease pathogenesis in respiratory disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have protective effects in animal models of ALI, asthma, pulmonary hypertension, and influenza pneumonia. These findings provide evidence to support the concept that apoA-I mimetic peptides might be developed into a new treatment that can either prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the lung is positioned to take a page from the cardiovascular disease playbook and utilize the protective properties of HDL and apoA-I as a novel therapeutic approach. Frontiers Media S.A. 2016-09-21 /pmc/articles/PMC5030281/ /pubmed/27708582 http://dx.doi.org/10.3389/fphar.2016.00323 Text en This work is authored by Elizabeth M. Gordon, Debbie M. Figueroa, Amisha V. Barochia, Xianglan Yao and Stewart J. Levine on behalf of the US Government and, as regards Drs. Gordon, Figueroa, Barochia, Yao and Levine and the US Government, is not subject to copyright protection in the United States. Foreign and other copyrights may apply. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Gordon, Elizabeth M. Figueroa, Debbie M. Barochia, Amisha V. Yao, Xianglan Levine, Stewart J. High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title | High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title_full | High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title_fullStr | High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title_full_unstemmed | High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title_short | High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease |
title_sort | high-density lipoproteins and apolipoprotein a-i: potential new players in the prevention and treatment of lung disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030281/ https://www.ncbi.nlm.nih.gov/pubmed/27708582 http://dx.doi.org/10.3389/fphar.2016.00323 |
work_keys_str_mv | AT gordonelizabethm highdensitylipoproteinsandapolipoproteinaipotentialnewplayersinthepreventionandtreatmentoflungdisease AT figueroadebbiem highdensitylipoproteinsandapolipoproteinaipotentialnewplayersinthepreventionandtreatmentoflungdisease AT barochiaamishav highdensitylipoproteinsandapolipoproteinaipotentialnewplayersinthepreventionandtreatmentoflungdisease AT yaoxianglan highdensitylipoproteinsandapolipoproteinaipotentialnewplayersinthepreventionandtreatmentoflungdisease AT levinestewartj highdensitylipoproteinsandapolipoproteinaipotentialnewplayersinthepreventionandtreatmentoflungdisease |